DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
Queen Mary University of London
Londres, Reino UnidoPublicaciones en colaboración con investigadores/as de Queen Mary University of London (39)
2023
-
Atezolizumab Plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)
Clinical Cancer Research, Vol. 29, Núm. 21
-
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
Annals of Oncology
-
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
Annals of Oncology, Vol. 34, Núm. 3, pp. 289-299
-
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)
Nature Medicine
-
Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma
European Urology
2022
-
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
Cancer, Vol. 128, Núm. 11, pp. 2085-2097
-
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy
British Journal of Clinical Pharmacology, Vol. 88, Núm. 7, pp. 3182-3192
-
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
European Urology, Vol. 82, Núm. 2, pp. 212-222
-
First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial
European Urology, Vol. 81, Núm. 3, pp. 266-271
-
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial
Nature communications, Vol. 13, Núm. 1, pp. 1878
-
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Clinical Cancer Research, Vol. 28, Núm. 10, pp. 2050-2060
2021
-
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 4, pp. 525-537
-
Enfortumab vedotin in previously treated advanced urothelial carcinoma
New England Journal of Medicine, Vol. 384, Núm. 12, pp. 1125-1135
-
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancer
Future Oncology, Vol. 17, Núm. 2, pp. 137-149
-
Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma
European Urology Focus, Vol. 7, Núm. 5, pp. 1084-1091
-
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice
The Journal of urology, Vol. 206, Núm. 2, pp. 240-251
-
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial Carcinoma
The Journal of urology, Vol. 205, Núm. 2, pp. 414-419
-
Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial
European urology oncology, Vol. 4, Núm. 3, pp. 456-463
-
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
Nature, Vol. 595, Núm. 7867, pp. 432-437